Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.43 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341768 | 1.00 | AURKA (0.43) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL341767 | 1.00 | AURKA (0.43) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342274 | 0.93 | AURKA (0.42) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342276 | 0.93 | AURKA (0.42) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342275 | 0.93 | AURKA (0.42) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342120 | 0.87 | AURKA (0.38) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342540 | 0.87 | AURKA (0.38) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342121 | 0.87 | AURKA (0.38) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342119 | 0.87 | AURKA (0.38) | AURKAPDPK1AURKBSYKBTK | |
| SCHEMBL342541 | 0.87 | AURKA (0.38) | AURKAPDPK1AURKBSYKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | AURKA 1/4885PDPK1 1729/4885AURKB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.